Pneumococcal pneumonia

A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom

INTRODUCTION

Pneumococcal disease (PD) significantly contributes to morbidity and mortality, carrying substantial economic and public health burden. This article is a targeted review of evidence for pneumococcal vaccination in the UK, the definitions of groups at particular risk of PD and vaccine effectiveness.

AREAS COVERED

Relevant evidence focusing on UK data from surveillance systems, randomized controlled trials, observational studies and publicly available government documents is collated and reviewed. Selected global data are included where appropriate.

EXPERT OPINION

National vaccination programs have reduced the incidence of vaccine-type PD, despite the rising prominence of non-vaccine serotypes in the UK. The introduction of higher-valency conjugate vaccines provides an opportunity to improve protection against PD for adults in risk groups. Several incentives are in place to encourage general practitioners to vaccinate risk groups, but uptake is low-suboptimal particularly among at-risk individuals. Wider awareness and understanding among the public and healthcare professionals may increase vaccination uptake and coverage. National strategies targeting organizational factors are urgently needed to achieve optimal access to vaccines. Finally, identifying new risk factors and approaches to risk assessment for PD are crucial to ensure those at risk of PD can benefit from pneumococcal vaccination.

Estimating population-based incidence of community-acquired pneumonia and acute otitis media in children and adults in Ontario and British Columbia using health administrative data, 2005-2018: a Canadian Immunisation Research Network (CIRN) study

BACKGROUND

There is a paucity of data on the burden of the full spectrum of community-acquired pneumonia (CAP) and acute otitis media (AOM) from outpatient and inpatient settings across the age spectrum.

METHODS

We conducted a population-based retrospective study in Ontario and British Columbia (BC), Canada, to estimate the incidence rate of CAP and AOM in children and adults over a 14-year period using health administrative databases. CAP and AOM cases were identified from outpatient physician consultation and hospitalisation data in both provinces, and from emergency department visit data in Ontario.

RESULTS

During 2005-2018, Ontario had 3 607 124 CAP, 172 290 bacterial CAP, 7814 pneumococcal pneumonia, and 8 026 971 AOM cases. The incidence rate of CAP declined from 3077/100 000 in 2005 to 2604/100 000 in 2010 before increasing to 2843/100 000 in 2018; bacterial CAP incidence rate also declined from 178/100 000 in 2005 to 112/100 000 in 2010 before increasing to 149/100 000 in 2018. The incidence rate of AOM decreased from 4192/100 000 in 2005 to 3178/100 000 in 2018. BC had 970 455 CAP, 317 913 bacterial CAP, 35 287 pneumococcal pneumonia and 2 022 871 AOM cases. The incidence rate of CAP in BC decreased from 2214/100 000 in 2005 to 1964/100 000 in 2010 before increasing to 2176/100 000 in 2018; bacterial CAP incidence rate increased from 442/100 000 in 2005 to 981/100 000 in 2018. The incidence rate of AOM decreased from 3684/100 000 in 2005 to 2398/100 000 in 2018. The incidence rate of bacterial CAP increased with age in older adults (≥65 years) with the highest burden in the oldest cohort aged ≥85 years both before and after 13-valent pneumococcal conjugate vaccine (PCV13) programme in both provinces. Hospitalised pneumococcal pneumonia decreased slightly but non-hospitalised pneumococcal pneumonia increased in BC during PCV13 period. No consistent direct benefit of PCV13 on CAP was observed in the paediatric population.

CONCLUSIONS

There is a substantial burden of CAP and AOM in Ontario and BC. Indirect benefits from childhood PCV vaccination and polysaccharide vaccination of older adults have not substantially decreased the burden of pneumococcal pneumonia in older adults.

A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK

INTRODUCTION

The burden of pneumococcal disease in older UK adults remains substantial. Higher valency pneumococcal conjugate vaccines (PCVs) are currently in development with adult formulations for two of these anticipated to become available in 2022. This article collates and reviews relevant candidate data now available that may be used to support cost effectiveness assessments of vaccinating immunocompetent UK adults aged ≥65-years with PCVs.

AREAS COVERED

This article uses published data from surveillance systems, randomized controlled trials and observational studies. It focuses on local data from the UK but where these are either limited or not available relevant global data are considered.

EXPERT OPINION

The body of relevant data now available suggests the UK is well placed to assess the cost effectiveness of vaccinating immunocompetent ≥65-year olds with new generation higher valency PCVs. Recent contemporary data provide important new and robust insights into the epidemiology of pneumococcal disease in older UK adults and help to address much of the uncertainty and data gaps associated with previous analyses. Using these data to make informed decisions about use of new higher valency PCVs for routine use in older adults will be important for public health in the UK.

Serotype distribution and antimicrobial Susceptibility of Streptococcus pneumoniae isolated from patients with pneumococcal pneumonia

Introduction: Streptococcus pneumoniae is a major cause of community-acquired pneumonia (CAP). In Serbia, pneumococcal conjugate vaccines PCV-10 and PCV-13 were licensed for immunization in 2018. Aim: The aim of this study was to evaluate serotype distribution and antimicrobial susceptibility of S. pneumoniae isolated from patients with pneumococcal pneumonia. Material and methods: Isolates of S. pneumoniae were recovered from patients with CAP addmitted to 18 hospitals throughout Serbia from 2012-2020. Confirmation of the identification was performed using lytA gene detection by PCR. Serotyping and antimicrobial susceptibility testing was performed by Quellung reaction and disk diffusion/gradient test, respectively. Interpretation of the susceptibility testing was done according to the current European Committee on Antimicrobial Susceptibility Testing recommendations. Results: During the study period, a total of 100 isolates of S. pneumoniae were collected. Overall, 19 pneumococcal serotypes were identified. The predominant types observed, in order of decreasing frequency, were 3 (37%), 14 (16%), 6B (6%), 7F (5%), 9V (4%), and 4 (4%); further, 2% of the isolates were non-typeable. However, the most common serotype among children < 2 years old was 14 (27.3%). The vaccine coverage of strains isolated from children < 5 years was higher with PCV-13 compared to PCV-10 (86,7% vs. 46,7%, p = 0.008). Additionally, the vaccine coverage of pneumococci isolated from patients >2 years was higher with the PPV-23 than with PCV-13 (96.6% vs. 84.3%, p = 0.0230). Ten isolates (10%) were PPV-23/nonPCV-13, whereas four isolates (4%) were non-typable (17A, 23A, and 9A). Serotype 3 significantly increased from pre-vaccine to post-vaccine period (30.8% vs. 60.8%, p = 0.0108). The overall antimicrobial resistance rates were as follows: penicillin - 9%, ceftriaxone - 2%, erythromycin - 24%, clindamycin - 16%, tetracycline - 11%, and trimethoprim-sulfamethoxazole - 21%. Conclusion: More than 70% of the isolated strains belonged to the serotypes 3, 14, 6B, 9B, and 4. The highest resistance rates of the tested pneumococci were found for macrolides and trimethoprim-sulfamethoxazole.